Introduction
============

Diabetes mellitus (DM) has detrimental effects on multiple organs in our body ([@B38]), including the heart ([@B5]). DM causes diabetic cardiomyopathy (DCM), a heart muscle disease independent of coronary artery disease, hypertension, or valvular disease, which leads to cardiac dysfunction ([@B35]). DCM and cardiac dysfunction can be evaluated by different methods including echocardiography ([@B6]; [@B4]; [@B27]; [@B19]; [@B34]), pressure-volume loop ([@B26]; [@B20]) and magnetic resonance imaging (MRI) ([@B17]; [@B22]). Echocardiography is a non-invasive method that utilizes ultrasound to measures mitral flow and cardiac dimension. A limitation to echocardiography is manual variability especially in positioning echocardiographic probe and/or analyses of cardiac parameters. Pressure-volume loop is widely used for assessing hemodynamic changes in the heart. In this method, a probe is inserted into the left ventricular space of the heart without touching the ventricular wall and pressure--volume relationship is recorded during contraction-relaxation cycle of the heart. A major limitation of this method is its invasive nature. MRI uses magnetic field to generate radio-frequency signals from the hydrogen atoms of the tissue that minimizes manual errors ([@B39]). MRI is a non-invasive method with least manual variability, thus considered as a gold standard reference for evaluating cardiac function ([@B22]).

Previous echocardiography and pressure-volume loop- based studies demonstrate cardiac dysfunction in T1DM (reduced insulin secretion) and T2DM (insulin resistance) hearts ([@B5]; [@B18]; [@B34]). Although T2DM is more prevalent than T1DM, the latter could have more severe impact on cardiac pathology due to high fluctuations in the blood glucose levels ([@B5]; [@B9]). Ins2^+/-^ Akita is a spontaneous, chronic, non-obese, genetic mouse model of T1DM where mutation in insulin 2 gene, which is orthologous to human insulin, causes T1DM ([@B42]; [@B40]). It is relevant to humans because mutation in insulin gene causes T1DM in humans ([@B14]). Although there is no controversy on T1DM phenotype of Akita, there are contrasting reports on their cardiac pathology and dysfunction. An echocardiography and tissue Doppler-based study demonstrates an early diastolic dysfunction with preserves systolic function in 12- and 24-week Akita (Ins2 ^WT/C96Y^) ([@B4]). Another echocardiography-based study shows no significant change in cardiac parameters in 20-, 36-, and 54-week Akita, except the reduced left ventricular developed pressure in 24-week Akita that suggests a modest left ventricular dysfunction ([@B6]). A speckle-tracking-based study reveals abnormal cardiac deformation in 12-week Akita ([@B43]). Hemodynamic study using pressure-volume loop shows reduced ± dp/dt and ejection fraction in 12- to 14-week Akita ([@B20]). Thus, there is controversy on cardiac dysfunction in Akita. Although MRI is a better method for evaluating cardiac dysfunction ([@B22]), to our knowledge, no MRI study has been done so far to evaluate cardiac dysfunction in Akita. Thus, the focus of our present study is to measure cardiac dysfunction in Akita using MRI. Akita develops hyperglycemia at 4-week and becomes robust hyperglycemic at 8--10 weeks (blood glucose level \>500 mg/dL). Because DM at initial stage develops diastolic dysfunction and at advanced stage develops systolic dysfunction ([@B5]), we sought to determine systolic dysfunction in 24-week Akita by measuring ejection fraction.

In addition to cardiac dysfunction, there is controversy on pathological cardiac remodeling in Akita. Hypertrophy and fibrosis contributes to pathological remodeling in the heart. A report on Akita heart shows no hypertrophy and fibrosis, even with elevated cardiac levels of β-myosin heavy chain, a molecular marker of hypertrophy ([@B4]). In contrast, other reports demonstrate increased cardiac hypertrophy ([@B10]; [@B33]) and fibrosis ([@B27]; [@B20]) in Akita. In streptozotocin-induced T1DM, another T1DM model system, shows increased cardiac hypertrophy ([@B12]) and fibrosis ([@B11]). Other clinical and animal-based studies show pathological remodeling in diabetic hearts ([@B9]; [@B18]; [@B34]). Thus, there is a controversy on whether Akita heart shows hypertrophy and fibrosis. To resolve the controversy, we aim to measure cardiac hypertrophy and fibrosis in 24-week Akita.

Diabetes mellitus leads to heart failure ([@B5]; [@B18]; [@B34]). Thus, developing a novel therapeutic strategy for DCM is translationally valuable. MicroRNAs (miRNAs) are a class of tiny, non-coding, regulatory RNAs ([@B3]). They are a promising therapeutic candidate for cardiovascular diseases ([@B28]). There are more than 800 miRNAs present in the human heart, where miR-133a is the most abundant miRNA ([@B23]). MiR-133a protects the heart against pathological remodeling by inhibiting hypertrophy ([@B7]; [@B12]) and fibrosis ([@B25]; [@B11]). Notably, miR-133a is downregulated in the diabetic hearts of humans ([@B31]) and rodents ([@B12]; [@B10]; [@B33]). Interestingly, overexpression of miR-133a mitigates cardiac hypertrophy ([@B33]), fibrosis ([@B11]), and contractile dysfunction ([@B33]) in different rodent models of diabetes. However, the role of miR-133a mimic in amelioration of cardiac remodeling and systolic dysfunction in Akita is unclear. In the present study, we aim to determine if miR-133a mimic treatment could ameliorate pathological cardiac remodeling and systolic dysfunction in Akita.

Materials and Methods {#s1}
=====================

Animal Experiments
------------------

We procured Ins2^+/-^ Akita (C57BL background) mice from The Jackson Laboratory (Bar Harbor, ME, United States) and bred them in the animal facility of the University of Nebraska Medical Center. We used 12-week male Akita and its sibling normoglycemic Ins2^+/+^ WT for experiments. Because miR-133a is reduced in Akita heart ([@B10]), we treated Akita with miR-133a mimic. We packaged miR-133a mimic or scrambled miRNA (control) into lentivirus ([@B33]) and administered 10^6^ virus particles/mice/one-time through tail vein injection. These mice were kept in the animal facility for 12-weeks. We performed MRI to measure cardiac dysfunction of WT, Akita, Akita treated with Lenti-miR-133a (Akita+miR) or Lenti-scrambled miRNA (Akita+scm) after 12-weeks (age of mice 24-week), and sacrificed them to collect the heart tissue for histological and molecular analyses (**Figure [1](#F1){ref-type="fig"}**). The breeding and experimental protocols were approved by the Institutional Animal Care and Use Committee and the Institutional Biosafety Committee of the University of Nebraska Medical Center.

![Schematic showing treatment regimen of Akita. **(A)** Lenti-miR-133a was created by packaging miR-133a mimic with lentivirus protein in 293FT cells and they were injected into Akita mice at the age of 12 weeks. **(B)** Lenti-scrambled was created in the same manner as Lenti-miR-133a except for replacing miR-133a mimic with scrambled miRNA. They were treated to Akita in the same manner as Lenti-miR-133a. **(C)** Flow schematic showing the timeline for genotyping, mice treatment, performance of cardiac-MRI, and sacrifice. WT, *N* = 5; Akita, *N* = 5; Akita+miR-133a, *N* = 5; and Akita+scm, *N* = 5.](fphys-09-01275-g001){#F1}

Lentivirus Packaging and Treatment
----------------------------------

The detailed method of lentivirus packaging and delivery into mice are described in **[Supplementary Material](#SM1){ref-type="supplementary-material"}** and in our previous publication ([@B33]). In brief, we transfected 293FT cells with GFP-tagged miR-133a or GFP-tagged scrambled miRNA vectors (cat \# MmiR3445-MR03 and cat\# CmiR0001-MR03, respectively, GeneCopoeia, Rockville, MD, United States) along with lentivirus protein coding genes VSVG, RSV-REV, and pMDLg/p RRE to generate miR-133a mimic-packaged (Lenti-miR-133a) or scrambled miRNA-packaged (Lenti-scrambled) lentivirus. We precipitated lentivirus by polyethylene glycol and through centrifugation, and calculated virus titer by infecting 293FT cells with different volumes of aliquoted virus.

Cardiac Magnetic Resonance Imaging (MRI)
----------------------------------------

We anesthetized mouse with inhalation anesthesia (1.5% isoflurane in 100% O~2~), placed the mouse in a Plexiglas holder, and then placed in a whole-body-quadrature-birdcage coil for imaging. The breathing rate of the anesthetized mouse was monitored continuously using an SA Instruments (Stony Brook, NY, United States) model 1025 small animal monitoring and gating system. MRI studies were done on a 7 Tesla MRI scanner (Bruker BioSpin 70/21, Ettlingen, Germany). The MR system was run with ParaVision 5.1 including the IntraGate software for sequence acquisition and reconstruction. Studies begin with a 3-plane gradient recalled localizer (TR = 15 ms TE = 1.69 ms NA = 15, total imaging time = 30 s) to center the animal in the magnet and coil. After localization and system shimming, the following image types were obtained on each mouse. A T1 weighted coronal RARE scan (TR = 1300 ms, TE = 9 ms, RARE factor = 4, 256 × 192 acquisition matrix, 40 mm FOV, 9 slices NA = 2, total imaging time = 2.08 min) for anatomical reference and to locate the cardiac muscle. T1 weighted single slice double oblique Intragate FLASH1 (256 × 256 matrix, 30 mm FOV, TE = 2.168 ms, TR = 8.5 ms, 200 images for a total imaging time of 7.68 min). Cardiac and respiratory compensates scans were then acquired to generate images with 10 phases through the cardiac cycle ([@B17]).

2D Cardiac Performance Analyses of MRI
--------------------------------------

Left ventricular (LV) function was assessed with steady state free-precession cine MR pulse sequence in the long-axis plane. CMR images were analyzed offline by a single observer (QS) using 2D cardiac performance analysis-MR (version 1.2.3.13, Edisonstrasse, Germany). The horizontal long axis was used for CMR-feature tracking analysis to derive LV longitudinal strain. The LV endocardial surfaces were manually traced by a point-and-click approach when the chamber was at its maximum size. The software, creating a region of interest, automatically generated an epicardial surface tracing. The region of interest was adjusted and automated tracking algorithm was applied. Tracking performance was reviewed to ensure accurate tracking of the ventricular myocardium, and when necessary, manual adjustments were made before the algorithm was reapplied. The software provided segmental and global values for strain in the long-axis view, as well as global ejection fraction.

RNA Extraction and miRNA Assay
------------------------------

The detailed protocols for RNA extraction and miRNA assay are described in our previous publications ([@B29]; [@B10]; [@B33]). In brief, we used mirVana miRNA Isolation Kit (cat \# AM1560, Life Technologies, United States) to extract miRNA. After confirming good quality RNA by NanoDrop 2000c (Thermo Fisher Scientific, Waltham, MA, United States), we made complimentary DNA using TaqMan^®^ MicroRNA reverse transcription kit (cat \# 4366597, Life Technologies, United States), and then amplified miRNA by qPCR using Taqman primers specific for miR-133a (Assay ID-002246, Life Technologies, United States) and U6 SnRNA (assay ID: 001973, Life Technologies, United States). U6 snRNA was endogenous control for miR-133a assay (**Figure [5](#F5){ref-type="fig"}**). We used Bio-Rad CFX qPCR instrument and analyzed the results by Bio-Rad CFX Manager3.0 software (Bio-Rad Laboratories, United States).

WGA Staining
------------

We performed standard wheat germ agglutinin (WGA) staining on 5 μm cryosections of the heart from the four groups of mice: WT, Akita, Akita treated with miR-133a mimic (Akita+miR), and Akita treated with scrambled miRNA (Akita+scm). The details of WGA staining are elaborated in our previous publication. In brief, we prepared heart cryosections by using CryoStar NX50 (Thermo Fisher Scientific, Waltham, MA, United States) and fixed them in 4% paraformaldehyde. We washed them with phosphate buffered saline (PBS) and then incubated them with 5 μg/ml of WGA (cat \# W834, Thermo Fisher Scientific, Waltham, MA, United States) for 10 min at room temperature. They were then washed, mounted with coverslip, and observed under a fluorescence microscope (EVOS, Life Technologies, United States). Representative WGA stainings of the heart from the four groups are presented in **Figures [3A](#F3){ref-type="fig"}, [7A](#F7){ref-type="fig"}**. We measured mean cardiomyocyte diameter (μm) in high magnification (40×) image. We randomly selected five areas (within the black open circle in **Figures [3C](#F3){ref-type="fig"}, [7C](#F7){ref-type="fig"}**) in the left ventricle and scored total 50 cells/per mouse from the five areas (10 cells/area). The mean cardiomyocytes diameter was quantified to determine cardiomyocytes hypertrophy.

Hematoxylin--Eosin Staining
---------------------------

Cryosections of left ventricle from the above-mentioned four groups of mice were fixed in 4% paraformaldehyde. The hematoxylin and eosin (H&E) staining was performed on these fixed sections following the kit protocol (cat \# HAE-1, ScyTeK Laboratories Inc., Logan, UT, United States) and observed under a bright-field microscope (Leica Microsystems, Buffalo Grove, IL, United States). The images were analyzed by the Image Pro7.0 software.

Picrosirius Red Staining
------------------------

To determine cardiac fibrosis, we performed picrosirius red staining. In brief, 10% formalin fixed left-ventricular paraffin sections (5 μm) were processed for picrosirius red staining. The reagents were Direct Red 80 (cat \# 365548) and picric acid (cat \# P6744-1GA) from Sigma Aldrich, St. Louis, MO, United States and glacial acetic acid (cat \# A38-500) from Thermo Fisher Scientific, Waltham, MA, United States. We used standard kit protocol for this staining. We used the Tissue Core facility of the University of Nebraska Medical Center for this staining.

Masson's Trichrome Staining
---------------------------

To corroborate the picrosirius red results, we used Masson's Trichrome staining where the blue color represents collagen (**Figures [4B](#F4){ref-type="fig"}, [8B](#F8){ref-type="fig"}**). The details of this protocol are described in our previous publication ([@B20]). We followed the kit protocol (Masson's Trichrome kit, cat \# 87019, Thermo Fisher Scientific, Waltham, MA, United States) to stain paraffin sections (5 μm) of the heart. We used bright-field VWR microscope and Motic Images Plus 2 imaging tool (Motic) for imaging. We calculated perivascular (PV) and interstitial (INT) fibrosis by quantifying % blue color pixel/total pixel using Image J software, NIH. We used the Tissue Core facility of the University of Nebraska Medical Center for Masson's Trichrome staining.

Statistical Analyses
--------------------

We evaluated cardiac dysfunction and histological analyses of the heart in random order and a blinded fashion. We presented statistical values as mean ± SD. We used two-tailed, unpaired Student's *t*-test to determine the difference between two groups. For miR-133a assay, we used one-way ANOVA followed by Tukey's multiple comparison test and values are presented as mean ± SEM. Graph Pad Prism 7 software was used for statistical analyses. A *P-*value of \<0.05 is considered statistically significant.

Results
=======

Akita Exhibits Systolic Dysfunction
-----------------------------------

To determine whether Akita exhibits systolic dysfunction, we performed MRI on WT and Akita hearts. We scored longitudinal strain in different parts of the heart (**Figure [2A](#F2){ref-type="fig"}**). We found that myocardial function was less aligned in Akita heart (**Figure [2A](#F2){ref-type="fig"}**) indicating myocardial dysfunction. Moreover, our MRI results showed reduced ejection fraction in Akita (**Figure [2B](#F2){ref-type="fig"}**). The short-axis view of MRI also supports cardiac dysfunction (**Figure [2C](#F2){ref-type="fig"}**). These findings demonstrate systolic dysfunction in Akita. Systolic dysfunction may result due to pathological cardiac remodeling, which was determined by cardiac hypertrophy and fibrosis.

![Measurement of cardiac dysfunction in Akita by MRI. **(A)** 2D cardiac performance analysis-MR tracking of left ventricle using long-axis MRI. The global longitudinal strains were recorded. **(B)** Analyses of cardiac ejection fraction by long-axis MRI. Values are represented as mean ± SD, *N* = 4--5 per group. **(C)** Representatives of short-axis images of the heart from WT and Akita mice. Two-tailed, unpaired Student's *t*-test was used for statistical analysis. *P* \< 0.05 is considered statistically significant.](fphys-09-01275-g002){#F2}

Akita Shows Cardiac Hypertrophy
-------------------------------

To investigate if Akita has cardiac hypertrophy, we performed WGA staining. WGA stains cell membrane (green) that helps to trace cardiomyocytes boundary (**Figure [3A](#F3){ref-type="fig"}**). We found that cardiomyocytes size was increased in the left ventricle of Akita (**Figures [3A,B](#F3){ref-type="fig"}**). To support the WGA results, we performed H&E staining that also shows cardiomyocytes size. The size of cardiomyocytes was comparatively larger and space between the cardiomyocytes was less in Akita (**Figure [3C](#F3){ref-type="fig"}**). The left ventricle region for hypertrophy measurement was kept identical in WT and Akita (black open circles) (**Figure [3C](#F3){ref-type="fig"}**) and the same area was used for the WGA staining and for the quantification of cardiomyocytes area.

![Measurement of cardiac hypertrophy in Akita. **(A)** Representative Wheat Germ Agglutinin (WGA) staining of the heart sections. Green color represents cardiomyocyte boundary and "^∗^" denotes a typical cardiomyocyte size. **(B)** Quantification of cardiomyocytes diameter. Values are presented as mean ± SD. *N* = 3 per group. Total number of cells scored for hypertrophy was 50. A minimum of five different fields of left ventricle was used from each mice. Two-tailed, unpaired Student's *t*-test was used for statistical analysis. *P* \< 0.05 is considered statistically significant. **(C)** Representative hematoxylin--eosin staining of left ventricular section. Outlined circles represent the area used for hypertrophic analysis.](fphys-09-01275-g003){#F3}

Akita Shows Cardiac Fibrosis
----------------------------

Cardiac fibrosis makes the heart stiffer and less compliant. To determine cardiac fibrosis, we performed picrosirius red staining. We found increased collagen deposition in picrosirius red stained Akita heart (**Figure [4A](#F4){ref-type="fig"}**), indicating increased cardiac fibrosis. To corroborate it, we performed Masson's Trichrome staining. We observed increased collagen deposition (blue color) in Akita heart in the perivascular (PV) and the interstitial (INT) regions (**Figure [4B](#F4){ref-type="fig"}**). We quantified the percentage area of fibrosis in the PV (**Figure [4C](#F4){ref-type="fig"}**) and the INT (**Figure [4D](#F4){ref-type="fig"}**) regions of the heart and found that fibrosis was increased in both regions of Akita heart (**Figures [4C,D](#F4){ref-type="fig"}**).

![Measurement of cardiac fibrosis in Akita by picrosirius red and Masson's Trichrome stainings. **(A)** Representative images of picrosirius red stained heart sections (left ventricle region) of WT and Akita mice. **(B)** Representative images of Masson's Trichrome stained heart sections of WT and Akita mice. Arrow shows collagen deposition (blue) in the heart. PV, perivascular area and INT, interstitial area **(C,D)**. Quantification of percentage fibrosis (pixel blue color area/total pixel area) by Image J in the four groups. Values are presented as mean ± SD. *N* = 3 per group was randomly selected for the fibrosis analyses. Two-tailed, unpaired Student's *t*-test was used for statistical analysis. *P* \< 0.05 is considered statistically significant.](fphys-09-01275-g004){#F4}

Altogether, the above findings demonstrate that Akita exhibits cardiac remodeling (increased hypertrophy and fibrosis) and systolic dysfunction (reduced ejection fraction).

MiR-133a Mimic Treatment Increases Cardiac miR-133a and Ameliorates Systolic Dysfunction in Akita
-------------------------------------------------------------------------------------------------

To validate that cardiac levels of miR-133a is reduced in Akita and miR-133a mimic treatment could increase cardiac levels of miR-133a in Akita, we treated Akita with Lenti-miR-133a (**Figure [1A](#F1){ref-type="fig"}**) or Lenti-scrambled (**Figure [1B](#F1){ref-type="fig"}**). We extracted the heart and measured cardiac levels of miR-133a in the treated and the untreated groups by individual miR-133a assay (**Figure [1C](#F1){ref-type="fig"}**). We found that cardiac levels of miR-133a was decreased in Akita (**Figure [5](#F5){ref-type="fig"}**). However, Lenti-miR-133a treatment increased miR-133a level in Akita heart (**Figure [5](#F5){ref-type="fig"}**). These results demonstrate that miR-133a mimic treatment has potential to increase cardiac levels of miR-133a in Akita. Then, we sought to determine whether the increased miR-133a in Akita heart improves systolic dysfunction. We performed cardiac MRI on miR-133a mimic-treated (Akita+miR) and scrambled miRNA-treated (Akita+scm) Akita. We found that miR-133a mimic treatment improved the alignment of myocardial movement as reflected by the tracing (**Figure [6A](#F6){ref-type="fig"}**). Notably, the ejection fraction of miR-133a mimic-treated Akita was improved (**Figure [6B](#F6){ref-type="fig"}**), which was also supported by the short-axis view (**Figure [6C](#F6){ref-type="fig"}**). These findings demonstrate that miR-133a mimic treatment could mitigate systolic dysfunction of Akita.

![Relative miR-133a expression by the individual miR-133a assay. RT-qPCR for miR-133a was performed on the left ventricle tissue of the heart using U6 snRNA as endogenous control. Akita+miR represents Akita treated with Lenti-miR-133a, and Akita+scm represents Akita treated with Lenti-scrambled miRNA. Values are represented as mean ± SEM, *N* = 3 per group. One-way ANOVA was used for statistical analysis followed by Tukey's multiple comparisons test. *P* \< 0.05 was considered as statistically significant.](fphys-09-01275-g005){#F5}

![miR-133a mimic treatment improves systolic dysfunction of Akita. **(A)** 2D cardiac performance analysis-MR tracking of left ventricle using long-axis MRI. The global longitudinal strains were recorded. **(B)** Analyses of cardiac percentage ejection fraction by long-axis MRI. **(C)** Representatives of short-axis and long-axis images of the heart. Values are represented as mean ± SD, *N* = 4--5 per group. Two-tailed, unpaired Student's *t*-test was used for statistical analysis. *P* \< 0.05 is considered statistically significant.](fphys-09-01275-g006){#F6}

MiR-133a Mimic Treatment Mitigates Pathological Cardiac Remodeling in Akita
---------------------------------------------------------------------------

DM-induced pathological remodeling contributes to cardiac dysfunction ([@B5]; [@B9]) and cardioprotective miR-133a has an anti-hypertrophy ([@B7]; [@B12]) and an anti-fibrotic ([@B25]; [@B11]) effects. To determine if miR-133a mimic treatment mitigates cardiac remodeling in Akita, we measured cardiac hypertrophy and fibrosis in miR-133a mimic-treated (Akita+miR) and scrambled miRNA-treated (Akita+scm) mice. We measured cardiac hypertrophy by WGA staining that demarcates cell boundary ([@B33]) and H&E staining (**Figure [7](#F7){ref-type="fig"}**), and cardiac fibrosis by picrosirius red and Masson's Trichrome staining (**Figure [8](#F8){ref-type="fig"}**; [@B20]). MiR-133a mimic treated-Akita showed decreased cardiac hypertrophy (**Figure [7](#F7){ref-type="fig"}**) and fibrosis (**Figure [8](#F8){ref-type="fig"}**) as compared to the scrambled miRNA-treated Akita (**Figures [7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}**). These results demonstrate that miR-133a mimic treatment mitigates T1DM-induced cardiac hypertrophy in Akita.

![miR-133a mimic treatment mitigates cardiac hypertrophy in Akita. **(A)** Representative Wheat Germ Agglutinin (WGA) staining of the heart (left ventricle) sections. Green color represents cardiomyocyte boundary and "^∗^" denotes a typical cardiomyocyte size. **(B)** Quantification of cardiomyocytes diameter. Values are presented as mean ± SD. *N* = 3 per group. Total number of cells scored for hypertrophy was 50. A minimum of five different fields of left ventricle was used from each mice. Two-tailed, unpaired Student's *t*-test was used for statistical analysis. *P* \< 0.05 is considered statistically significant. **(C)** Representative hematoxylin--eosin staining of left ventricular section. Outlined circles represent the area used for hypertrophic analysis.](fphys-09-01275-g007){#F7}

![miR-133a mimic treatment alleviates cardiac fibrosis in Akita **(A)**. Representative images of picrosirius red stained heart sections (left ventricle region) of Akita treated with miR-133a mimic (Akita+miR) or scrambled miRNA (Akita+scm). **(B)** Representative images of Masson's Trichrome staining of the heart sections of Akita+miR and Akita+scm. Arrow shows the collagen deposition (blue) in the heart. PV, perivascular area; INT, interstitial area **(C,D)**. Quantification of percentage fibrosis (pixel blue color area/total pixel area) by Image J in the four groups. Values are presented as mean ± SD. *N* = 3 per group was randomly selected for the fibrosis analyses. Two-tailed, unpaired Student's *t*-test was used for statistical analysis. *P* \< 0.05 is considered statistically significant.](fphys-09-01275-g008){#F8}

Altogether, these results demonstrate that miR-133a mimic treatment is cardioprotective to Akita. It alleviates cardiac remodeling and ameliorates systolic dysfunction in Akita.

Discussion
==========

In the present study, we demonstrate systolic dysfunction in Akita (**Figure [2](#F2){ref-type="fig"}**) using MRI method. MRI is a more reliable method than echocardiography and hemodynamic measurement methods ([@B22]). Thus, our MRI-based study gives strong basis to support cardiac dysfunction in Akita and resolves the controversy on it. To determine cardiac remodeling, we used two methods to assess cardiac hypertrophy and fibrosis. Our results demonstrate increased hypertrophy (**Figure [3](#F3){ref-type="fig"}**) and fibrosis (**Figure [4](#F4){ref-type="fig"}**) in Akita heart, supporting pathological cardiac remodeling in Akita ([@B27]; [@B10]; [@B33]; [@B20]). In addition, our results demonstrate that miR-133a mimic treatment increased cardiac levels of miR-133a (**Figure [5](#F5){ref-type="fig"}**) and ameliorates systolic dysfunction (**Figure [6](#F6){ref-type="fig"}**) and pathological remodeling (**Figures [7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}**) of Akita. These findings support the previous reports that miR-133a protects against T1DM-induced cardiac hypertrophy ([@B12]) and fibrosis ([@B11]). Based on these results, we conclude that reduced levels of miR-133a (anti-hypertrophy and anti-fibrosis) in Akita heart may contribute to cardiac hypertrophy and fibrosis resulting in cardiac dysfunction, and miR-133a mimic treatment to Akita could ameliorate T1DM-induced cardiac remodeling and systolic dysfunction (**Figure [9](#F9){ref-type="fig"}**).

![Schematics showing that T1DM decreases the cardiac levels of miR-133a, which induces cardiac hypertrophy and fibrosis and decreases percentage ejection fraction (% EF) that ultimately results in cardiac dysfunction and heart failure. MiR-133a mimic treatment mitigates T1DM-induced cardiac hypertrophy and fibrosis, increases EF and ameliorates cardiac dysfunction/heart failure.](fphys-09-01275-g009){#F9}

Empirical evidences support reduced cardiac miR-133a in Akita ([@B10]) and other models of T1DM ([@B12]; [@B11]). In our previous report, we have demonstrated that delivery of miR-133a packaged into lentivirus is able to increase the cardiac levels of miR-133a ([@B33]). Our present results validate decreased levels of miR-133a in Akita heart ([@B10]) and increased cardiac levels of miR-133a in miR-133a mimic-treated Akita heart ([@B33]; **Figure [5](#F5){ref-type="fig"}**). Because miR-133a is largely transcribed in the heart and skeletal muscle ([@B24]), the expression of injected miR-133a mimic should be largely in these organs. Accordingly, we found ∼6-fold increase in the cardiac levels of miR-133a in Akita heart after miR-133a mimic treatment. Recently, we found that miR-133a is present in the neurons of the periventricular region of the brain ([@B37]), thus we cannot rule out the systemic effects of miR-133a mimic treatment in Akita. This is a limitation of the present study. Future studies with cardiac-specific miR-133a transgenic mice would explain the specific impact of miR-133a overexpression in the heart on cardiac dysfunction in T1DM mice. However, the aim of this study was to determine whether the decreased miR-133a contributes to cardiac dysfunction in Akita heart. To that end, our results show decreased ejection fraction in Akita (**Figure [2](#F2){ref-type="fig"}**) suggesting systolic dysfunction in Akita. We believe that these findings resolve the controversy on cardiac dysfunction in Akita because MRI is a more reliable and unbiased measurement of cardiac dysfunction than the echocardiography and pressure-volume loop studies ([@B22]). These results also support the previous findings from echocardiography and pressure-volume loop studies that showed cardiac dysfunction in Akita ([@B6]; [@B27]; [@B20]). Moreover, we demonstrate that miR-133a overexpression could increase ejection fraction in Akita (**Figure [6](#F6){ref-type="fig"}**). Thus, miR-133a mimic could be a promising therapeutic candidate to ameliorate cardiac dysfunction in Akita and possibly in other models of T1DM.

To determine how miR-133a improves cardiac dysfunction in Akita, we aim to evaluate cardiac remodeling by measuring cardiac hypertrophy and fibrosis. Because miR-133a is an anti-hypertrophy ([@B7]; [@B12]) and an anti-fibrosis ([@B25]; [@B11]) miRNA and downregulated in Akita heart ([@B12]; [@B10]; [@B33]), it is presumed that reduced cardiac levels of miR-133a may contribute to cardiac remodeling in Akita. Our results of WGA (**Figures [3A,B](#F3){ref-type="fig"}**) and H&E (**Figure [3C](#F3){ref-type="fig"}**) show increased cardiac hypertrophy in Akita. It is also documented that β-myosin heavy chain (a hypertrophy marker) ([@B4]) and matrix metalloproteinase-9 (MMP9), a fibrosis marker, ([@B27]) are increased in Akita heart. However, a report shows no hypertrophy and fibrosis in Akita hearts ([@B4]). One possible reason for discrepancies in the results for pathological remodeling in Akita could be strain variation (we used C57BL/6-*Ins2 ^Akita^*/J, The Jackson Laboratory stock number 003548) and/or the age (24-week) of Akita.

MiRNAs play crucial regulatory roles in biological functions ([@B3]) and have emerged as a promising therapeutic candidate for cardiovascular diseases ([@B28]; [@B36]) and DCM ([@B30]; [@B15]; [@B32]). Previous studies from our laboratory focusing on transcriptome analyses of Akita heart by RNA-seq and microarray ([@B10]) and miRNA microarray ([@B20]) revealed several miRNAs that are differentially regulated in Akita heart. These studies also support that miR-133a is downregulated in Akita heart. Interestingly, overexpression of miR-133a in T1DM heart improves cardiac contractility ([@B33]) and mitigates cardiac fibrosis ([@B11]). In the present study, we demonstrate that miR-133a mimic treatment mitigates cardiac hypertrophy (**Figure [7](#F7){ref-type="fig"}**) and fibrosis (**Figure [8](#F8){ref-type="fig"}**) in Akita. Altogether, our findings provide a solid basis to demonstrate pathological remodeling in the Akita heart (**Figures [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}**) and also miR-133a as a therapeutic candidate to mitigate cardiac remodeling in Akita (**Figures [7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}**).

Our results from miR-133a mimic-treated Akita mice has translational value because DM prevalence is increasing around the world ([@B21]; [@B41]; [@B1]) and it increases the risk of heart failure ([@B16]; [@B13]; [@B18]). Clinical trial shows that tight control of hyperglycemia in diabetic patients could not reduce the risk of heart failure ([@B8]). Thus, the impetus to develop a novel therapeutic target for DCM is high. DM exacerbates mortality in patients with coronary disease ([@B16]). Reduced cardiac miR-133a is common in humans heart failure with coronary artery disease ([@B2]) and with DM ([@B31]). Thus, supplementing miR-133a could be a cardioprotective strategy to diabetic patients with coronary artery disease.

There are several critical aspects and limitations of the present study. First, miR-133a mimic treatment did not change blood glucose level in Akita (data not shown) suggesting that the mitigation of cardiac remodeling and improvement in systolic dysfunction of Akita by miR-133a mimic treatment is independent of glucose metabolic pathways. Second, the present study used a chronic model of T1DM (Akita), which may differ from acute model of T1DM (streptozotocin-induced T1DM). Thus, more studies on other models of T1DM are required to generalize the role of miR-133a in T1DM heart. Third, the study uses mice, and the results obtained from mice may not necessarily translate into humans. Therefore, further studies using human samples are required to support the role of miR-133a in DCM.
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